Showing 4601-4610 of 7240 results for "".
- ASDS Survey Highlights Teledermatology Boom, Staffing Challenges, and Other Ways COVID-19 Upended Practicehttps://practicaldermatology.com/news/asds-survey-sites-teledermatology-boom-staffing-challenges-and-other-ways-pandemic-upended-practice/2461070/From dramatic upticks in the use of teledermatology to staffing challenges and delays in procedures, the ongoing COVID-19 pandemic continues to affect dermatology practices and patients, according to a
- Lubriderm Launches Skin Scholarship with the National Hispanic Health Foundationhttps://practicaldermatology.com/news/lubriderm-launches-skin-scholarship-with-the-national-hispanic-health-foundation/2461030/Lubriderm is partnering with the
- ASDSA Honorees Recognized for Engagement in Initiatives that Benefit Dermatologic Surgery and Patientshttps://practicaldermatology.com/news/asdsa-honorees-recognized-for-engagement-in-initiatives-that-benefit-dermatologic-surgery-and-patients/2460995/The American Society for Dermatologic Surgery Association (ASDSA) announced the recipients of its annual awards this week during the ASDS / ASDSA Virtual Annual Meeting. ASDSA is proud to recognize its members who contribute significant time and expertise advocating for patient safety,
- PsA Treatment Snapshot: Study Highlights Trends in PsA Treatment Since 2018https://practicaldermatology.com/news/psa-treatment-snapshot-study-highlights-trends-in-psa-treatment-since-2018/2460985/There’s been a significant increase in anti-IL17 and anti-phosphodiesterase-4 (anti-PDE4) medications being used as initial treatment for psoriatic arthritis (PsA) since 2018, which may reflect their inclusion as potential initial therapy in the American College of Rheumatology/National Pso
- St. Ives Launches Social Media Contest to Help Reduce College Students' Financial and Skin Stresshttps://practicaldermatology.com/news/st-ives-launches-social-media-contest-to-help-reduce-college-students-financial-and-skin-stress/2460961/
- Study Highlights Severe AD, Depression Linkhttps://practicaldermatology.com/news/study-highlights-severe-ad-depression-link/2460907/Severe atopic dermatitis (AD) travels with depression, a new study shows. In a study of 11, 181 kids, severe AD was associated with an approximately 2-fold increase in the likelihood of symptoms of depression and internalizing symptoms across childhood, compared to eczema-free kids.&nbs
- Foods High in Sugar and Fat Disrupt the Gut Microbiome and Trigger Psoriasis Flareshttps://practicaldermatology.com/news/foods-high-in-sugar-and-fat-disrupt-the-gut-microbiome-and-trigger-psoriasis-flares/2460846/Diets rich in sugar and fat may lead to an imbalance in the gut’s microbial culture and contribute to inflammatory skin diseases such as psoriasis, according to a new study in the Journal o
- Can Blocking the Function of the CCR6 Chemokine Help Treat Psoriasis and Psoriatic Arthritis?https://practicaldermatology.com/news/can-blocking-the-function-of-the-ccr6-chemokine-help-treat-psoriasis-and-psoriatic-arthritis/2460825/A novel chemical blocker targeting chemokine proteins may significantly reduce skin and joint inflammation in psoriasis and psoriatic arthritis, according to a study in mice. Chemokines are small molecules with a critical role in the body’s response to inflammation and infection.
- AADA Statement on Legislative Interference in Health Care for Transgender Patientshttps://practicaldermatology.com/news/aada-statement-on-legislative-interference-in-health-care-for-transgender-patients/2460817/The American Academy of Dermatology Association strongly opposes recent efforts by state legislatures to restrict physicians’ ability to provide care to transgender youths. Legislation such as the bill enacted this spring in Arkansas as well as those proposed in several other states are a d
- Biosimilar News: Switching Study Shows Cyltezo and Humira Are Interchangeablehttps://practicaldermatology.com/news/biosimilar-news-switching-study-shows-cyltezo-and-humira-are-interchangeable/2460762/Switching between adalimumab biosimilar Cyltezo and its reference product results in similar pharmacokinetics, efficacy, safety and immunogenicity in people with moderate-to-severe chronic plaque psoriasis, according to new Phase 3 data presented at the American Academy of Dermatology 2021 virtua